224 related articles for article (PubMed ID: 15296501)
1. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).
Qunibi WY
Kidney Int Suppl; 2004 Sep; (90):S8-S12. PubMed ID: 15296501
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
Qunibi WY; Nolan CR
Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
[TBL] [Abstract][Full Text] [Related]
3. The CARE study and cardiovascular calcification.
Qunibi WY
Manag Care; 2006 Mar; 15(3 Suppl):1-5. PubMed ID: 16604943
[TBL] [Abstract][Full Text] [Related]
4. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
5. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients.
Levin NW; Hoenich NA
Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):563-8. PubMed ID: 11496047
[TBL] [Abstract][Full Text] [Related]
6. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
Block GA; Hulbert-Shearon TE; Levin NW; Port FK
Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
Nolan CR; Qunibi WY
Kidney Int Suppl; 2005 Jun; (95):S13-20. PubMed ID: 15882308
[TBL] [Abstract][Full Text] [Related]
8. Importance of hyperphosphataemia in the cardio-renal axis.
Goodman WG
Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i4-8. PubMed ID: 15126647
[TBL] [Abstract][Full Text] [Related]
9. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
10. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.
Block GA; Port FK
Am J Kidney Dis; 2000 Jun; 35(6):1226-37. PubMed ID: 10845841
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.
Qunibi WY; Nolan CA; Ayus JC
Kidney Int Suppl; 2002 Dec; (82):S73-80. PubMed ID: 12410860
[TBL] [Abstract][Full Text] [Related]
12. [Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].
Douthat WG; Alles A; Marinovich S; Tirado S; Peñalba A; Prudkin S
Nefrologia; 2003; 23 Suppl 2():95-9. PubMed ID: 12778863
[TBL] [Abstract][Full Text] [Related]
13. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
14. [Front line of management of hyperphosphatemia in hemodialysis patients].
Yumita S
Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
[TBL] [Abstract][Full Text] [Related]
15. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences.
Llach F
Kidney Int Suppl; 1999 Dec; 73():S31-7. PubMed ID: 10633461
[TBL] [Abstract][Full Text] [Related]
17. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
[TBL] [Abstract][Full Text] [Related]
19. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
20. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
